Wolfgang Eiermann, MD

Professor Eiermann
Professor Eiermann

Professor of Gynecology

Medical studies in Tübingen and Munich

1976 - 1982 Residency at the University of Munich Hospital under the direction of Prof. Dr. K. Richter
1983 - 1991 Attending Physician, Obstetrics and Gynecology, University of Munich Hospital
Research period at Beth Israel Hospital, Harvard Medical School, Boston
1991 - 2011 Director of the Frauenklinik vom Roten Kreuz, Munich
2001 - present Medical Director, Frauenklinik vom Roten Kreuz
Certified in gynecological oncology
2010 Awarded an honorary doctorate by the Petrov Cancer Center, University of St. Petersburg, Russia

Professor Eiermann is an internationally recognized expert in the treatment of breast cancer and gynecological oncology. While serving as director at the Frauenklinik vom Roten Kreuz, Munich, he established a nationally and internationally recognized center for gynecological oncology alongside the general practice of obstetrics and gynecology. This has since become one of the largest breast cancer treatment centers in Germany.

In addition to his clinical work, he has been particularly active in developing new therapies for breast cancer. He has served as a research director and consultant in a variety of national and international studies on the optimization of breast cancer treatment. He was involved in the clinical development of Herceptin since 1995 and has been an innovator in intraoperative radiotherapy for breast cancers.

Several times, most recently in 2014, Professor Eiermann was named one of Germany's top physicians by the national magazine FOCUS.

His research successes have been documented in scientific publications and book chapters.

Professor Eiermann has now joined the Interdisciplinary Oncology Center and offers medical cancer therapies and comprehensive treatment of all gynecological diseases including surgeries at the neighboring ISAR Klinikum. He continues to serve as an oncology consultant for important pharmaceutical research companies.


  • Steering Committee Translational Research in Oncology (TRIO) USA

  • Board member of the Michelangelo Foundation, Milan (Cancer Research)

  • American Society of Clinical Oncology (ASCO)

  • German Breast Group (GBG)

  • International Steering Committee TARGIT Group (London)

  • Board member of the Walter Schulz Foundation for Medical Research on Cancer

  • Member of the Tumor Center Munich

  • Member of the German Society for Gynecology and Obstetrics (DGGG)

  • Member of the German Society for Senology (DGS)

  • Editorial and scientific advisory boards of several national and international journals